Polyclonal Antibody to Monocyte Chemotactic Protein 2 (MCP2)
| Code | Size | Price |
|---|
| PAA088Eq01-20ul | 20ul | £93.00 |
Quantity:
| PAA088Eq01-100ul | 100ul | £176.00 |
Quantity:
| PAA088Eq01-200ul | 200ul | £238.00 |
Quantity:
| PAA088Eq01-1ml | 1ml | £550.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species:
- Equine (Horse)
- Horse
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CCL8; CCL-8; SCYA8; MCP-2; HC14; Chemokine C-C-Motif Ligand 8; Small Inducible Cytokine Subfamily A(Cys-Cys)Member 8; Monocyte Chemoattractant Protein 2
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Monocyte Chemotactic Protein 2
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Monocyte Chemotactic Protein 2 (MCP2) | RPA088Eq01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||